Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum
October 05 2016 - 12:06PM
Marketwired
LOS ANGELES, CA-(Marketwired - Oct 5, 2016) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a pharmaceutical company developing novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases, today announced that the Company's
Chief Executive Officer, Michael Step, presented at the 4th
Microbiome R&D Business Collaboration Forum & Panel on
October 4, 2016 in San Diego, CA.
Mr. Step presented an overview of RP-G28, Ritter's lead product
candidate which has the potential to become the first FDA-approved
drug for the treatment of lactose intolerance, and its Phase 2b/3
clinical trial which is expected to have top-line data in early
2017.
Presentation Title: Pioneering Development in the Gut Microbiome
Panel Discussion: Exploring the Potential of Prebiotics
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products
that modulate the human gut microbiome to treat gastrointestinal
diseases. The Company is advancing human gut health research by
exploring the metabolic capacity of gut microbiota, and translating
the functionality of these microbiome modulators into safe and
effective applications. Their lead drug candidate, RP-G28, has the
potential to become the first FDA-approved drug for lactose
intolerance, a condition that affects more than one billion people
worldwide.
Forward-Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Ritter
Pharmaceuticals' management. Such statements involve a number of
known and unknown risks and uncertainties that could cause the
Company's future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Any
statements contained herein that do not describe historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. These forward-looking
statements are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information
ContactsInvestor Contact: David Burkedburke@theruthgroup.com
(646) 536-7009 Media Contact: Chris
Hippolytechippolyte@theruthgroup.com 646.536.7023
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024